Stem cell therapy · 2026
Stem cell therapy
in China,
by NMPA standards.
China’s first approved MSC drug (Ruibosheng, Jan 2025). 2,794 registered clinical trials. The most active regulated regenerative-medicine pipeline outside the US. Class A hospitals, GMP-grade cellular products, $8,400–$24,000 all-in.
Jan 2025
First MSC drug approved
Ruibosheng (amimestrocel injection) — NMPA approval
NMPA, 2025
2,794
Registered clinical studies
Stem cell trials on China Clinical Trial Registry
ChiCTR, 2024
4
NMPA-approved CAR-T
Yikaida, Carteyva, Fukerui, Yuanruida
NMPA, 2024
$8.4–24k
Autologous MSC all-in
Vs $30,000–$80,000 in US private clinics
Industry data
Class A
All partner facilities
NMPA-licensed GMP-grade cellular labs
NHC / NMPA
12 mo
Follow-up included
Telehealth review with operating physician
Panda Touring Care
The case
Regulated, evidence-graded,
and clinically active.
Stem cell therapy in China is regulated by the NMPA and delivered through Class A hospitals with NMPA-licenced GMP-grade cellular labs — not the unregulated wild-west tourism market many associate with stem cell treatment in some countries.
In January 2025, NMPA approved Ruibosheng (amimestrocel injection) — China’s first approved MSC drug, indicated for steroid-refractory acute GVHD. China’s clinical trial registry (ChiCTR) lists 2,794 active stem cell trials, more than any country except the US.
For international patients, this means access to evidence-graded protocols at regulated facilities — not 'stem cell tourism.' Panda Touring Care places ~3,000 patients per year through partner Class A hospitals including Beijing 301, Shanghai Ruijin, Boao Lecheng and HKU-Shenzhen.
Therapy types
Six types of cellular therapy.
Autologous MSC 自体间充质干细胞
Your own cells — harvested from bone marrow, adipose tissue, or (if available) umbilical cord. No rejection risk. Best for OA, autoimmune, post-injury.
$8.4–24k
Allogeneic MSC 异体MSC
Donor cells, typically umbilical cord-derived. Standardised dose, no harvest delay, immunomodulatory advantage. Used for GVHD, autoimmune, severe OA.
$10–28k
Exosome therapy 外泌体
Extracellular vesicles secreted by stem cells. Used for inflammatory and degenerative conditions. Lower cost; emerging evidence.
$6–15k
NK-cell immunotherapy
Natural killer cell expansion and infusion. Adjunct in oncology supportive care; investigational for some autoimmune.
$15–35k
CAR-T cellular therapy
4 NMPA-approved products for B-cell lymphoma, ALL, multiple myeloma. ~⅓ the US price.
$60–140k
iPSC / ESC trials
Induced pluripotent and embryonic stem cell programs (Parkinson's, retinal disease, diabetes) — research-stage at top academic centres.
Trial-only
Conditions
Where the evidence is strongest.
Knee osteoarthritis
Multiple Chinese RCTs show pain and function improvement with autologous MSC vs hyaluronic acid. Standard adjunct or pre-arthroplasty option.
Graft-versus-host disease
Ruibosheng (amimestrocel) — China's first NMPA-approved MSC drug — indicated for steroid-refractory acute GVHD.
Rheumatoid arthritis & SLE
Allogeneic MSC infusion shows immune modulation in active autoimmune disease. Used as adjunct to DMARDs in selected refractory cases.
Spinal cord injury
Combined intrathecal MSC + intensive rehabilitation in subacute phase; modest motor improvement in selected patients.
Type 2 diabetes
Allogeneic MSC infusion for β-cell support — Chinese trials show HbA1c and C-peptide improvements; durability variable.
COPD & pulmonary fibrosis
MSC infusion via IV or inhaled exosomes — small Chinese RCTs suggest functional improvement.
Evidence grades reflect aggregate quality of randomised trials and systematic reviews as of 2024. NMPA-approved indication: GVHD only (Ruibosheng). All other indications are off-label or trial-stage. Discuss honestly with a senior physician.
The patient pathway
Six steps from inquiry
to 12-month follow-up.
Case review
Submit medical records, imaging, current medications. Senior physician determines candidacy and recommends MSC type, dose and protocol within 5–7 business days.
Itemized quote
Receive written quote covering cell processing, treatment, hospitalization, accommodation, coordinator. Compare 2–3 hospital options if appropriate.
M-visa & travel
Panda Touring Care issues hospital invitation letter (3–5 days). M-visa application 5–15 business days. Book flexible-date flight.
On-site consultation & harvest
Day 1–2: consultation, baseline imaging and labs. For autologous: cell harvest from bone marrow / adipose / cord. For allogeneic: donor cell matching. Cell processing 7–14 days.
Infusion & recovery
Cell infusion under medical supervision (IV, intra-articular, or intrathecal depending on indication). On-site recovery 7–14 days with monitoring. Discharge when surgeon clears.
12-month follow-up
Telehealth review at week 2, 6, month 3, 6, 12 — with secure imaging upload. Operating physician remains primary clinician of record. Bilingual records throughout.
FAQ
Stem cell therapy in China, answered.
- Is stem cell therapy legal in China?
- Yes. Since the 2015 regulatory reform, autologous and allogeneic mesenchymal stem cell (MSC) treatments are regulated by the National Medical Products Administration (NMPA) and the National Health Commission. Treatments must be performed in approved Class A hospitals using GMP-grade cellular products. In January 2025, NMPA approved Ruibosheng (amimestrocel injection) — China's first approved MSC drug. China currently has the most active regulated regenerative medicine pipeline outside the United States.
- What stem cell treatments are available in China?
- Three categories: (1) Mesenchymal stem cells (MSC) — autologous (your own cells) and allogeneic (donor cells); the most evidence-supported and widely practised; (2) Exosome therapy — extracellular vesicles secreted by stem cells, used for inflammatory and degenerative conditions; (3) Immune cell therapy — NK cells, CAR-T (NMPA-approved for B-cell lymphoma, ALL, multiple myeloma), and TCR-T trials. iPSC and embryonic stem cell trials are active in research settings.
- What conditions does stem cell therapy treat?
- Strong evidence: graft-versus-host disease (GVHD — Ruibosheng's approved indication), knee osteoarthritis, autoimmune conditions (RA, SLE), spinal cord injury rehabilitation, chronic wounds and burns. Moderate evidence: type 2 diabetes (β-cell regeneration), neurodegenerative conditions (Parkinson's, Alzheimer's — research stage), cardiac repair post-MI, COPD. The honest answer: evidence is strongest for GVHD and orthopedic OA; weaker but promising for systemic inflammatory and degenerative conditions.
- How much does stem cell therapy cost in China?
- All-in pricing including coordinator and 14-day stay: autologous MSC therapy $8,400–$24,000 depending on cell count, dose protocol and condition complexity; allogeneic MSC $10,000–$28,000; exosome protocols $6,000–$15,000; NK-cell immunotherapy $15,000–$35,000; CAR-T $60,000–$140,000 (vs $400,000+ in the US). Pricing varies by hospital and individualised protocol — request itemized quotes.
- Is stem cell therapy safe?
- When performed at NMPA-licenced GMP-grade facilities, the safety profile is well-characterised. Major published trials of autologous MSC for OA and GVHD report serious adverse events at <1%. Common minor effects (transient fever, injection-site discomfort) occur in ~10% and resolve within 24–48 hours. The principal safety risks are: contamination from non-licensed labs; exaggerated efficacy claims; herb/drug interactions with concurrent medications. Always work with NMPA-licensed Class A facilities — Panda Touring Care only partners with these.
- Where in China should I go for stem cell therapy?
- Top centres: Beijing 301 PLA General Hospital (cellular therapy lab, comprehensive); Beijing PUMC International Department; Shanghai Ruijin Hospital (haematology and stem cell research flagship); Renji Hospital Shanghai (CAR-T leader); Boao Lecheng Pilot Zone (Hainan — special regulatory zone for advanced regenerative therapies); HKU-Shenzhen Hospital (English-first); Peking University Shenzhen Hospital. All operate NMPA-licensed cellular therapy facilities.
- What's the difference between autologous and allogeneic?
- Autologous: your own cells, harvested from bone marrow, adipose tissue or umbilical cord (if you're young). No rejection risk; well-suited to most orthopedic and inflammatory conditions; processing 7–14 days. Allogeneic: donor cells from cord blood or umbilical cord tissue (typically). Off-the-shelf availability (no harvest delay); standardised dose; some immunomodulatory advantage. Both are clinically established; your physician will recommend based on indication and timeline.
- Can foreigners receive stem cell therapy in China?
- Yes. International patients access stem cell therapy through dedicated international medical departments at Class A hospitals with full English-speaking coordination. Panda Touring Care has placed ~3,000 international patients per year into licensed cellular protocols at Beijing 301, Shanghai Ruijin, Boao Lecheng and other partner facilities. Process: case review → eligibility assessment → M-visa → on-site consultation + cell harvest (autologous) or matching (allogeneic) → infusion → 14-day on-site recovery → 12-month telehealth follow-up.
Explore the cluster
Types of Stem Cell Therapy
Autologous vs allogeneic MSC, exosomes, NK cells — protocol differences and when each is used.
Read on typesConditions Treated
Evidence-graded review across orthopedic, autoimmune, neurology, oncology and more.
See conditionsCost Guide
All-in pricing, what's included, comparison with US and Korean private clinics.
See costsResearch Briefing
Deep dive on China's regenerative medicine research landscape — trials, approvals, papers.
Read the researchCAR-T Therapy
4 NMPA-approved CAR-T products for B-cell lymphoma, ALL, multiple myeloma.
Read on CAR-TMedical Tourism in China
How stem cell therapy fits into a broader medical-tourism trip.
Read the guideHonest candidacy
assessment, free.
Submit your records and a 30-minute video review with a senior physician will tell you straight whether stem cell therapy can help — and what realistic outcomes look like for your condition.